Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEW-AGE

Financiado

Cerrado

A next generation platform for catalysing pre clinical development of drugs agai...

A next generation platform for catalysing pre clinical development of drugs against Alzheimer s and other degenerative diseases of old age Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditi... ver más

31/07/2018

UNIVDUN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-07-31

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVDUN

149.96K€ | Lider

BODEGAS ESCUDERO

303.76K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DESARROLLO DE NUEVOS FÁRMACOS NEUROPROTECTORE... DESARROLLO DE NUEVOS FÁRMACOS NEUROPROTECTORES Y MÉTODOS DIA... 1M€ Cerrado

NeuronAgeScreen A Drug Discovery and Target Identification Screening Platfor... 150K€ Cerrado

SAF2016-76520-R PAPEL DE NRF2 EN LA FUNCION Y EL DESTINO DEL CEREBRO CON ALZ... 411K€ Cerrado

BIO2013-48222-R DESARROLLO DE NUEVAS ESTRATEGIAS TERAPEUTICAS, BASADAS EN PH... 288K€ Cerrado

SAF2010-22114-C02-02 ALTERACIONES EN LA FUNCIONALIDAD E INTERACCIONES DE PROTEINA... 121K€ Cerrado

SAF2009-07600 ESTUDIO DEL PROCESO DE AGREGACION DE LA PROTEINA B-AMILOIDE... 175K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2017-01-26
Fecha Fin: 2018-07-31

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditions including Alzheimer’s and Parkinson’s, which have been described as the greatest unmet need facing modern medicine. Developing new therapies to slow, halt, or reverse these pathologies is regarded as a key element in addressing this global health priority. No such therapies have been successfully developed to date. A major unsolved challenge faced by drug discovery organisations is that for most degenerative conditions, there are no prognostic markers that can be used to predict whether a candidate therapy is likely to improve clinical outcome. Our solution to this problem exploits the fact that the pathogenesis and progression of all degenerative diseases is associated with oxidative stress. Oxidative stress thus makes an excellent potential prognostic biomarker, but it has been difficult to measure in vivo. Now, under the REDOX ERC Advanced Investigator Award, we have developed a portfolio of next-generation mouse models in which oxidative stress can be monitored at single-cell resolution across all organs. Moreover, the measurements can also be performed non-invasively and in real-time. We believe that these mice provides a new platform with unprecedented utility that can be used by drug-discovery organisations to accelerate, reduce the costs, and increase the predictive power of their pre-clinical pipelines for degenerative conditions. To support commercial exploitation of these models, we will: a) Show that our oxidative stress biomarkers are elevated in mouse models for two degenerative conditions, Alzheimer’s and Hutchinson-Gilford Progeria Syndrome. b) Demonstrate that the biomarker signals are reduced in mice administered therapies believed to be disease-modifying.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores